First US Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product
Go back to First US Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product| TRANS-LUX CORPORATION (NYSE: TLX) | Delayed: 0.29 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.29 | 52 Week High | $2.18 | |||
| Open | $25.79 | 52 Week Low | $0.30 | |||
| Day High | $0.29 | P/E | N/A | |||
| Day Low | $0.29 | EPS | $-3.32 | |||
| Volume | 373,793 | |||||
